Skip to main content
Premium Trial:

Request an Annual Quote

Federal Court Whittles Down Fluidigm Lawsuit Against IonPath

NEW YORK – A federal judge has narrowed a patent infringement lawsuit filed by Fluidigm by dismissing some of the firm's claims against competitor IonPath. Fluidigm's allegations of direct infringement remain, however, and the court did leave open the possibility for the firm to file an amended complaint to address the deficiencies in the case.

On Friday, following a hearing the day before, Judge William Alsup of the US District Court for the Northern District of California granted defendant IonPath's motion to dismiss claims of intentional interference with contractual relations, contributory infringement, induced infringement, and enhanced damages.

Fluidigm sued IonPath in September, alleging infringement of two patents for mass cytometry technology and tortious interference with Fluidigm's contractual relationships with customers.

IonPath, based in Menlo Park, California, is commercializing MIBIscope, a mass spectrometry-based multiplexed protein imaging system that the firm says will compete with Fluidigm's Hyperion mass cytometry platform.

Alsup noted, "defendant does not challenge patent owners' claims of direct infringement, thus those claims proceed."

He also gave Fluidigm permission to file an amended complaint by Feb. 13. "This order highlighted certain deficiencies in the amended complaint," Alsup wrote, "but it will not necessarily be enough to add sentences parroting each missing item identified herein. If patent owners move for leave to file yet another amended complaint, they should be sure to plead their best case."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.